Coastal Research Institute | Fayetteville, NC

Research site

(Unclaimed)

Location

2139 Valleygate Drive, Suite 101B, Fayetteville, North Carolina, United States of America

Site insights

Top conditions

Top treatments

Resmetirom

HU6

Deudomperidone

Survodutide

Tenapanor

Cilofexor

Enobosarm

Amine

Glecaprevir

Semicarbazide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 18 total trials

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess th...

Enrolling

Chronic Idiopathic Constipation (CIC)

Drug: Tenapanor 50 mg BID

Drug: Tenapanor 5 mg BID

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Active, not recruiting

NASH

Cirrhosis, Liver

Drug: Resmetirom

Drug: Placebo

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high d...

Enrolling

Metabolic Dysfunction-associated Steatohepatitis

Drug: Placebo

Drug: ECC4703

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants wi...

Enrolling

Non-alcoholic Fatty Liver Disease

Metabolic Dysfunction-Associated Steatohepatitis

Drug: Efimosfermin

Drug: Placebo

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) (AMPLIFY)

Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagn...

Enrolling

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Drug: HU6

Other: Placebo

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis

Combination Product: Survodutide

Combination Product: Placebo matching survodutide

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

This study is open to adults who are at least 18 years old living with obesity and have:* a confirmed liver disease called non-alcoholic steatohepati...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Liver Fibrosis

Combination Product: Placebo

Combination Product: Survodutide